EARUM PHARMACEUTICALS | RAYMED LABS | EARUM PHARMACEUTICALS/ RAYMED LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -43.7 | -7.7 | - | View Chart |
P/BV | x | 2.0 | - | - | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
EARUM PHARMACEUTICALS RAYMED LABS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
EARUM PHARMACEUTICALS Mar-23 |
RAYMED LABS Mar-23 |
EARUM PHARMACEUTICALS/ RAYMED LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 8 | 2 | 406.9% | |
Low | Rs | 2 | 1 | 130.2% | |
Sales per share (Unadj.) | Rs | 2.3 | 0 | - | |
Earnings per share (Unadj.) | Rs | 0.3 | -0.4 | -80.2% | |
Cash flow per share (Unadj.) | Rs | 0.3 | -0.4 | -87.5% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 3.0 | -5.4 | -56.2% | |
Shares outstanding (eoy) | m | 61.68 | 4.27 | 1,444.5% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.2 | 0 | - | |
Avg P/E ratio | x | 15.9 | -4.4 | -361.4% | |
P/CF ratio (eoy) | x | 15.1 | -4.6 | -332.3% | |
Price / Book Value ratio | x | 1.7 | -0.3 | -516.1% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 316 | 8 | 4,186.9% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 1 | 0 | 200.0% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 141 | 0 | - | |
Other income | Rs m | 23 | 0 | 10,776.2% | |
Total revenues | Rs m | 164 | 0 | 77,881.0% | |
Gross profit | Rs m | 9 | -2 | -498.4% | |
Depreciation | Rs m | 1 | 0 | 2,080.0% | |
Interest | Rs m | 3 | 0 | - | |
Profit before tax | Rs m | 28 | -2 | -1,634.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 8 | 0 | - | |
Profit after tax | Rs m | 20 | -2 | -1,158.5% | |
Gross profit margin | % | 6.6 | 0 | - | |
Effective tax rate | % | 29.1 | 0 | - | |
Net profit margin | % | 14.1 | 0 | - |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 281 | 0 | 562,140.0% | |
Current liabilities | Rs m | 99 | 1 | 10,962.2% | |
Net working cap to sales | % | 129.4 | 0 | - | |
Current ratio | x | 2.8 | 0.1 | 5,128.0% | |
Inventory Days | Days | 0 | 0 | - | |
Debtors Days | Days | 2,173 | 0 | - | |
Net fixed assets | Rs m | 5 | 2 | 315.9% | |
Share capital | Rs m | 123 | 43 | 288.6% | |
"Free" reserves | Rs m | 64 | -66 | -96.8% | |
Net worth | Rs m | 187 | -23 | -811.2% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 286 | 2 | 18,323.1% | |
Interest coverage | x | 10.6 | 0 | - | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.5 | 0 | - | |
Return on assets | % | 7.9 | -109.5 | -7.3% | |
Return on equity | % | 10.6 | 7.4 | 142.9% | |
Return on capital | % | 16.5 | 7.4 | 222.7% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 0 | 0 | - | |
Fx outflow | Rs m | 0 | 0 | - | |
Net fx | Rs m | 0 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3 | -2 | -160.4% | |
From Investments | Rs m | NA | 2 | 0.0% | |
From Financial Activity | Rs m | -3 | NA | - | |
Net Cashflow | Rs m | 0 | 0 | - |
Indian Promoters | % | 0.0 | 28.4 | - | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 1.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 100.0 | 71.6 | 139.6% | |
Shareholders | 58,634 | 1,504 | 3,898.5% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare EARUM PHARMACEUTICALS With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | EARUM PHARMACEUTICALS | RAYMED LABS. | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -1.95% | 0.00% | 0.15% |
1-Month | -7.93% | 4.82% | 0.33% |
1-Year | -31.05% | 11.68% | 54.36% |
3-Year CAGR | -38.34% | 36.97% | 14.52% |
5-Year CAGR | -15.97% | -0.08% | 20.24% |
* Compound Annual Growth Rate
Here are more details on the EARUM PHARMACEUTICALS share price and the RAYMED LABS. share price.
Moving on to shareholding structures...
The promoters of EARUM PHARMACEUTICALS hold a 0.0% stake in the company. In case of RAYMED LABS. the stake stands at 28.4%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of EARUM PHARMACEUTICALS and the shareholding pattern of RAYMED LABS..
Finally, a word on dividends...
In the most recent financial year, EARUM PHARMACEUTICALS paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of 0.0%.
RAYMED LABS. paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of EARUM PHARMACEUTICALS, and the dividend history of RAYMED LABS..
For a sector overview, read our pharmaceuticals sector report.
Indian share markets Slipped further as the session progressed and ended the day weak.